Kymera Therapeutics to Participate in Upcoming June Investor Conferences
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events:
- Jefferies 2024 Global Healthcare Conference in New York, NY on June 5 at 11:30 a.m. ET; and
- Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on June 11 at 2:40 p.m. ET.
Live webcasts of the presentations will be available under “” in the Investors section of the Company’s website at Replays of the webcasts will be archived and available following the events.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit or follow us on (previously ) or .
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
857-285-5300
